Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review 2024: Drug Code/INN, Patent/Expiry, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
October 24, 2024 09:59 ET
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides...
Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review 2024
February 23, 2024 07:31 ET
|
Research and Markets
Dublin, Feb. 23, 2024 (GLOBE NEWSWIRE) -- The "Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides...
Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review 2023
December 14, 2023 05:48 ET
|
Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides...